276 results about "Cell activation" patented technology

The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The present invention relates to regulation of lymphocyte activation. In particular, it relates to compositions and methods for regulating lymphocyte activation by selectively binding multiple cell surface antigens expressed by the same lymphocyte.

A method and apparatus for dynamically activating and deactivating a supplementary cell in Dual-Cell HSDPA service of a Universal Mobile Communication Service (UMTS) system. In a supplementary cell activation and deactivation method, a user equipment receives a supplementary cell activation command from a base station; compares an uplink transmission power with a predetermined threshold value; transmits a supplementary cell activation reply, when the uplink transmission power is equal to or greater than the threshold value; and transmits a supplementary cell deactivation reply, when the uplink transmission power is less than the threshold value.

Disclosed are cells, methods of modulating cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. Immune modulation including alteration of cytokine profile, cytotoxic activity, antibody production and inflammatory states is achieved through the administration of various cell types that have been unmanipulated or manipulated in order to endow specific biological activity. Cellular subsets and administration of the subsets in combination with various agents are also provided. One embodiment teaches the previously unknown finding that adipose tissue derived mononuclear cells contain T cells with immune regulatory properties that alone or synergistically with various stem cells induce immune modulation upon administration. Another embodiment is the finding that stimulation of stem cell activation results in stem cell secondary activation of immune modulatory cells, one type which is T regulatory cells (Tregs). One specific embodiment involves extraction of a heterogenous stem cell pool, which contains T regulatory cells, treatment in culture of the population with agents known to stimulate stem cell activation, then subsequent extraction and administration of the purified Tregs. Other embodiments include expansion of Tregs in the presence of antigen in order to generate anti-specific Tregs.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

An algorithm which considers the individual power consumption profiles for different types of base stations in a heterogeneous cellular network, and determines which base stations can be switched OFF in line with the traffic demand. The algorithm predicts (302) a spatially-accurate network load; calculates (304) the best serving BS for each load region; investigates (308-318) toads on Pico cells with respect to a threshold, and ranks (320) candidate Pico cells to be switched OFF in order of least power efficiency and most resource efficiency. Pico cells determined to remain on are fully loaded (322) allowing more candidates to be switched OFF (324). The algorithm optimizes the energy efficiency of the heterogeneous, cellular network, enabling the activation of the minimum number of base stations to support the predicted traffic demand for a given time period and allowing significant energy savings for the operator.

The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).

Embodiments of the invention provide devices or methods that include a status bit representing an inversion of stored data. New data is written to selected cells, the new data is selectively inverted, and the status bit is selectively toggled, based on a comparison between pre-existing data and new data associated with a write command. A benefit of embodiments of the invention is that fewer memory cells must be activated in many instances (when compared to conventional art approaches). Moreover, embodiments of the invention may also reduce the average amount of activation current required to write to variable resistive memory devices and other memory device types.

A light guide comb that produces a direct massage effect on the head of a user, and, moreover, uses light rays to promote cell activation of the head, cortical layer and acupuncture points, while simultaneously stimulating hair follicles to promote the health and growth of hair. The light guide comb includes an upper shell, a lower shell, a compartment, a light stimulation device and a light guide. A plurality of guide holes are defined in the upper shell to correspond to a plurality of guide pins configured on the light guide. Light rays produced by the light stimulation device disposed within the compartment are propagated through the plurality of guide pins and transmitted outward. A plurality of massage knobs are disposed on a comb head of the lower shell to provide a massage surface area greater than that of the plurality of guide pins.

A method, apparatus and computer program product are provided in order to enhance network notification of secondary cell activation. In a first embodiment, the method includes receiving a secondary cell activation command, activating a secondary cell, and transmitting a PHR indicating activation of the secondary cell. In a second embodiment, the method includes receiving a secondary cell activation command, activating a secondary cell, and transmitting a signal indicating an expected time period until activation of the secondary cell. In a third embodiment, the method may optimize implicit SCell deactivation by receiving a secondary cell activation command, activating a secondary cell, receiving a PDCCH order for an uplink grant or a downlink assignment, and starting a secondary cell deactivation timer associated with the secondary cell in response to receiving the PDCCH order. A corresponding apparatus and computer program product are also provided.

The present invention provides bradykinin peptide analogs, compositions, and methods of inhibiting thrombin-induced platelet and other cell activation. The bradykinin analogs comprise single or multiple peptide segments. The invention also provides a method for identifying compounds that selectively inhibit thrombin-induced platelet and other cell activation.

Methods and apparatus are provided for controlling transition of an operation state of a cell in a wireless communication system. The cell includes a transceiver configured to transmit and receive signals to and from a terminal and another cell. The cell also includes a controller configured to transition an operation state of the cell from an active state to a dormant state, transmit a discovery signal, determine whether a cell activation signal is received from a node that controls the cell, and transition the operation state of the cell from the dormant state to the active state when the cell activation signal is received.

The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.

This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.

The invention discloses a far infrared heat insulation wind coat, which comprises an inner layer and an outer layer, wherein the inner layer is formed by mercerized cloth through mixed weaving, the outer layer is formed by cotton and hemp through mixed weaving, a heat insulation sandwich layer is arranged between the inner layer and the outer layer, the heat insulation sandwich layer is a far infrared heat insulation plus material, and the inner layer, the outer layer and the sandwich layer are closed through adopting zippers. The far infrared heat insulation wind coat has the advantages that the affinity with the skin of the human body is good, a good health care function is realized, the infrared heat insulation sandwich layer has the excellent heat insulation function, the cell activation function can also be realized, old and dead cells can be discharged, or the regeneration capability is given to the old and dead cells, the cell energy can be enhanced, and the effects of enhancing the functions and the activity of the cells and the like are realized. The far infrared heat insulation wind coat has the advantages that the heat insulation effect is excellent, the durability is high, and good heat insulation performance is still realized after the washing for many times.

The embodiments of the invention provide a method for acquiring secondary timing advance (TA) and equipment. The method comprises the following steps that: after a terminal receives a secondary cell activation command, or after the secondary cell is activated, if a secondary time alignment timer (TAT) of the secondary cell is not operated, the terminal initiates an random access process, wherein the secondary TA of the secondary cell is different from primary TA of a primary cell; and the terminal obtains the secondary TA according to the received TA during the random access process. According to method for acquiring secondary TA and equipment provided in the embodiments of the invention, after the secondary cell activation command emitted by a base station is received or the secondary cell is activated, the terminal initiates the random access process so as to obtain the secondary TA, thereby saving signaling cost and system resources.

The invention discloses a Chinese herbal extract for promoting hair growth and hair blacking and improving dandruff and application thereof. The extract is obtained by extraction of bulk drugs containing ginseng, American ginseng, polygonum multiflorum, rhubarb, dodder and other 57 traditional Chinese medicines. Specifically, each of the traditional Chinese medicines accounts for 0.5wt%-30wt%, and the total composition of the traditional Chinese medicines is 100wt%. The bulk drugs are grinded into powder, the powder is mixed with an organic solvent and water, and then extraction is carried out to obtain the Chinese herbal extract. After extraction, the bulk drugs can release a restoration leading factor, which can promote cell activation and has the function of promoting cell proliferation. Thus, the Chinese herbal extract provided by the invention can be applied to activation of hair follicle cells, activation of melanin cells and other aspects, and can be used as a skin, hair follicle and hair medicine related to the fields, or can be used as an active and auxiliary component of cosmeceutical products associated with the fields.

This invention relates to a method and flow control devices based on output queue based on the control devices. This invention mainly includes: Based on the cell output ports on the cell line and from different angles to achieve statistical count queue scheduling and flow control. In such a system, flow control and queue management is separate; Queue Management referred directly applied cell activation, the flow control is not mentioned directly dependent on Queue Management in cell survey results, but through the cell's priority, output ports, the source of cell chips, and other point of view, using different combinations of cell counting statistics, and on this basis to achieve flow control. Accordingly, the present invention can participate in the realization of the queue scheduling less number of simple, easy-to-manage, cells scheduling easy to be realized.

The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rejection. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab')2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. Examples of monoclonal antibodies, which bind to and inhibit C5, were generated and are designated MAb 137-76 and MAb 137-30.